Leadership & Pay ·
INmune Bio appoints R. Duane Clark II and James Sapirstein to its board of directors
INMBInmune Bio, Inc.
INmune Bio, Inc. appointed R. Duane Clark II and James Sapirstein as independent directors on September 8, 2026, increasing the Board size to seven members. Both executives bring over 40 years of biopharmaceutical leadership; Mr. Clark currently serves as General Manager for U.S. Rare Diseases at Sanofi, while Mr. Sapirstein is CEO of Cocrystal Pharma and former CEO of Entero Therapeutics. Each director received an initial option to purchase 100,000 shares vesting over three years, a $50,000 annual cash retainer payable quarterly, and standard indemnification agreements. The appointments aim to strengthen the Board's capabilities in rare-disease commercialization for Ebstrocel™ and business development for strategic partnerships as the company advances its late-stage pipeline toward potential regulatory filings and commercialization. INmune Bio is a late-stage biotechnology company focused on developing treatments targeting the innate immune system for inflammation, immunology, and neuroinflammation.